Summary of Study ST001495

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001013. The data can be accessed directly via it's Project DOI: 10.21228/M8RH7J This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001495
Study TitleEffects of Synbiotic Administration on Fecal Microbiome and Metabolomic Profiles of Dogs receiving Antibiotics
Study Typeuntargeted metabolomics
Study SummaryEffect of antibiotics on fecal microbiome and metabolome
Institute
University of California, Davis
DepartmentCollege of Biological Sciences
LaboratoryWest Coast Metabolomics Center
Last NamePaglia
First NameKelly
Address451 Health Sciences Drive, Room 1313
Emailkpaglia@ucdavis.edu
Phone5307528129
Submit Date2020-09-24
Raw Data AvailableYes
Raw Data File Type(s)cdf
Analysis Type DetailGC-MS
Release Date2020-10-13
Release Version1
Kelly Paglia Kelly Paglia
https://dx.doi.org/10.21228/M8RH7J
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001013
Project DOI:doi: 10.21228/M8RH7J
Project Title:Effects of Synbiotic Administration on Fecal Microbiome and Metabolomic Profiles of Dogs receiving Antibiotics
Project Type:Double-blind randomized controlled trial
Project Summary:The purpose of this study was to compare the fecal microbiome and metabolome of dogs administered enrofloxacin and metronidazole, followed by either a placebo or a bacterial/yeast synbiotic combination, for 21 days with reevaluation 8 weeks after treatment. Fecal samples were collected on days 5-7 (baseline), 26-28, and 82-84. The fecal microbiome was analyzed by qPCR and sequencing of 16S rRNA genes; time-of-flight mass spectrometry was used to determine metabolomic profiles. Split plot repeated measures ANOVAs were used to compare results between treatment groups. P < 0.05 was considered significant, with Benjamini & Hochberg’s False Discovery Rate used to adjust for multiple comparisons. Alpha diversity metrics differed significantly over time in both treatment groups, with incomplete recovery by days 82-84. Beta diversity and the dysbiosis index differed significantly over time and between treatment groups, with incomplete recovery at days 82-84 for dogs in the placebo group. Significant group-by-time interactions were noted for 15 genera, including Adlercreutzia, Bifidobacterium, Slackia, Turicibacter, Clostridium, [Ruminococcus], Erysipelotrichaceae_g_, [Eubacterium], and Succinivibrionaceae_g_. Group and time effects were present for six genera, including Collinsella, Ruminococcaceae_g_, and Prevotella. Metabolite profiles differed significantly by group-by-time, group, and time for 28, 20, and 192 metabolites, respectively. These included short-chain fatty acid, bile acid, tryptophan, sphingolipid, benzoic acid, and cinnaminic acid metabolites, as well as fucose and ethanolamine. Changes in many taxa and metabolites persisted through days 82-84.
Institute:University of Tennessee
Department:College of Veterinary Medicine
Laboratory:Small Animal Clinical Sciences
Last Name:Whittemore
First Name:Jacqueline
Address:2407 River Drive, Knoxville TN 37996
Email:jwhittemore@utk.edu
Phone:865-974-8387
Funding Source:Nutramax Laboratories Veterinary Sciences, Inc., Lancaster, SC

Subject:

Subject ID:SU001569
Subject Type:Mammal
Subject Species:Canis lupus familiaris
Taxonomy ID:9615

Factors:

Subject type: Mammal; Subject species: Canis lupus familiaris (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA125950Re_1_006Placebo
SA125951Re_2_030Placebo
SA125952Sar_1_011Placebo
SA125953Ra_3_053Placebo
SA125954Ra_2_029Placebo
SA125955Lu_3_055Placebo
SA125956Ra_1_005Placebo
SA125957Sar_2_035Placebo
SA125958Sy_1_003Placebo
SA125959Ty_2_038Placebo
SA125960Ty_3_062Placebo
SA125961Bi_1_023Placebo
SA125962Ty_1_014Placebo
SA125963Sy_3_051Placebo
SA125964Lu_2_031Placebo
SA125965Sy_2_027Placebo
SA125966Sar_3_059Placebo
SA125967Re_3_054Placebo
SA125968Cu_1_008Placebo
SA125969Cu_2_032Placebo
SA125970Cu_3_056Placebo
SA125971Ca_3_064Placebo
SA125972Ca_2_040Placebo
SA125973Bi_2_047Placebo
SA125974Lu_1_007Placebo
SA125975Ca_1_016Placebo
SA125976Gu_1_012Placebo
SA125977Bi_3_071Placebo
SA125978Ki_1_019Placebo
SA125979Ki_3_067Placebo
SA125980Gu_2_036Placebo
SA125981Ji_3_058Placebo
SA125982Ki_2_043Placebo
SA125983Ji_2_034Placebo
SA125984Gu_3_060Placebo
SA125985Ji_1_010Placebo
SA125986Po_1_018Synbiotic
SA125987Po_3_066Synbiotic
SA125988Po_2_042Synbiotic
SA125989Pa_2_033Synbiotic
SA125990Ro_1_004Synbiotic
SA125991Ma_3_050Synbiotic
SA125992Pa_1_009Synbiotic
SA125993Pa_3_057Synbiotic
SA125994Sak_3_069Synbiotic
SA125995To_2_044Synbiotic
SA125996To_3_068Synbiotic
SA125997Ma_2_026Synbiotic
SA125998To_1_020Synbiotic
SA125999Sak_2_045Synbiotic
SA126000Ro_3_052Synbiotic
SA126001Sak_1_021Synbiotic
SA126002Ro_2_028Synbiotic
SA126003Al_1_013Synbiotic
SA126004Fr_1_022Synbiotic
SA126005Fr_2_046Synbiotic
SA126006Fr_3_070Synbiotic
SA126007Bo_3_065Synbiotic
SA126008Bo_2_041Synbiotic
SA126009Al_2_037Synbiotic
SA126010Al_3_061Synbiotic
SA126011Bo_1_017Synbiotic
SA126012Gi_1_015Synbiotic
SA126013Gi_2_039Synbiotic
SA126014Ja_1_024Synbiotic
SA126015Ja_2_048Synbiotic
SA126016Ja_3_072Synbiotic
SA126017Go_3_049Synbiotic
SA126018Go_2_025Synbiotic
SA126019Gi_3_063Synbiotic
SA126020Go_1_001Synbiotic
SA126021Ma_1_002Synbiotic
Showing results 1 to 72 of 72

Collection:

Collection ID:CO001564
Collection Summary:Lyophilized feces
Sample Type:feces

Treatment:

Treatment ID:TR001584
Treatment Summary:2, 36, Synbiotic, Placebo

Sample Preparation:

Sampleprep ID:SP001577
Sampleprep Summary:Dog, Feces, 72, 10-30 mg, Lyophilized feces

Combined analysis:

Analysis ID AN002478
Analysis type MS
Chromatography type GC
Chromatography system LECO Pegasus IV GC-time of flight mass spectrometers
Column Restek Rtx-5Sil (30m x 0.25mm,0.25um)
MS Type EI
MS instrument type GC-TOF
MS instrument name Leco Pegasus IV TOF
Ion Mode POSITIVE
Units normalized peak height

Chromatography:

Chromatography ID:CH001815
Chromatography Summary:Primary metabolism by GCTOF
Instrument Name:LECO Pegasus IV GC-time of flight mass spectrometers
Column Name:Restek Rtx-5Sil (30m x 0.25mm,0.25um)
Chromatography Type:GC

MS:

MS ID:MS002298
Analysis ID:AN002478
Instrument Name:Leco Pegasus IV TOF
Instrument Type:GC-TOF
MS Type:EI
MS Comments:A Leco Pegasus IV time of flight mass spectrometer is controlled by the Leco ChromaTOF software vs. 2.32 (St. Joseph, MI). The transfer line temperature between gas chromatograph and mass spectrometer is set to 280°C. Electron impact ionization at 70V is employed with an ion source temperature of 250°C. Acquisition rate is 17 spectra/second, with a scan mass range of 85-500 Da.
Ion Mode:POSITIVE
  logo